Survival in triple-negative breast cancer patients with post-neoadjuvant residual disease treated with adjuvant capecitabine
Capecitabine in breast cancer
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Arnon J. Oviedo-Tábora, Elsa M. Vásquez-Trespalacios, Fernanda X. Bravo-Muñoz, Javier M. Cuello-Lopez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
DOI:
https://doi.org/10.33821/745Keywords:
triple-negative breast cancer, Capecitabine, ARB, residual disease, disease free survival, overall survivalAbstract
Background: The scarcity of effective therapies has contributed to poor outcomes in triple-negative breast cancer. Objective: To evaluate overall and progression-free survival in patients with triple-negative breast cancer with post-neoadjuvant residual disease, treated with Capecitabine. Methods: Retrospective cohort study. Kaplan-Meier survival functions were calculated. Additionally, Cox regression models were developed for association analysis. Results: Forty-one patients were included, of whom 25 (61%) were postmenopausal, 23 (56.1%) had initial tumors ?5.1cm. The median PFS was 25.03 months (95% CI, 13.37 - 36.68). Twenty six percent of patients had progression at 36 months follow-up, 54.5% of those who had progression were premenopausal. In women with postmenopausal status, higher PFS was observed (HR0.32, 95% CI 0.09 -0.98, p 0.045). The median OS was 55.60 months (95% CI, 46.5-58.5). There was no significant difference between the RCB (Residual Cancer Burden) score and PFS and OS. Conclusion: favorable results were observed in patients with post-neoadjuvant residual disease treated with adjuvant Capecitabine, particularly in postmenopausal patients with less previous tumor size.
Downloads
References
Gonzalez L, Bardach A, Palacios A, Peckaitis C, Ciapponi A, Pichón-Riviere A, Augustovski F. Health-Related Quality of Life in Patients with Breast Cancer in Latin America, and the Caribbean: A Systematic Review and Meta-Analysis. Oncologist. 2021 May;26(5): e794-e806. https://doi.org/10.1002/onco.13709
The Global Cancer Observatory - All Rights Reserved - 2020. https://gco.iarc.fr/
Bianchini, G., De Angelis, C., Licata, L. et al. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. Nat Rev Clin Oncol. 2021;19, 91-113. https://doi.org/10.1038/s41571-021-00565-2
Lang Y, Chai Q, Tao W, Liao Y, Liu X, Wu B. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer. Breast. 2023 Apr;68: 173-80. https://doi.org/10.1016/j.breast.2023.02.003
Tarantino P, Gandini S, Trapani D, Criscitiello C, Curigliano G. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2021 Mar;159: 103223. https://doi.org/10.1016/j.critrevonc.2021.103223
Miglietta F, Dieci MV, Griguolo G, Guarneri V. Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. Cancer Treat Rev. 2021 Jul;98: 102222. https://doi.org/10.1016/j.ctrv.2021.102222
Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol 2021. JCO2003399. https://doi.org/10.1200/JCO.20.03399
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365: 1687-717. https://doi.org/10.1016/S0140-6736(05)66544-0
Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet 2012;379: 432-44. https://doi.org/10.1016/S0140-6736(11)61625-5
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384: 164-72. https://doi.org/10.1016/S0140-6736(13)62422-8
?ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis?awek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021 Aug 25;13(17): 4287. https://doi.org/10.3390/cancers13174287
Szymiczek A, Lone A, Akbari MR. Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review. Clin Genet. 2021 May;99(5): 613-37. https://doi.org/10.1111/cge.13900
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A , Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-159. https://doi.org/10.1056/NEJMoa1612645
Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz JA, Torres R, de la Haba J, García-Martínez E, Gómez HL, Llombart A, Bofill JS, Baena-Cañada JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López -Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martín M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020 Jan 20;38(3): 203-13. https://doi.org/10.1200/JCO.19.00904
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008 Apr;61(4): 344-9. https://doi.org/ 10.1016/j.jclinepi.2007.11.008.
Sitio web ADRES: https://www.adres.gov.co/consult-su-eps
Ye F, Bian L, Wen J, Yu P, Li N, Xie X, Wang X. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials. BMC Cancer. 2022 Mar 12;22(1): 261. https://doi.org/10.1186/s12885-022-09326-5
Wang X, Wang J, He Y, Li J, Wang T, Ouyang T, et al. Observation Effectiveness of Dose-Dense Neoadjuvant Anthracycline Sequential Weekly Paclitaxel for Triple-Negative Breast Cancer Patients. Breast Cancer Clin. 2023 Jun;23(4): 423-30. https://doi.org/10.1016/j.clbc.2023.02.009
Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Kast K, Jackisch C, Thomalla J, Ingold-Heppner B, Blohmer JU, Rezai M, Frank M, Engels K, Rhiem K, Fasching PA, Nekljudova V, von Minckwitz G, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomized phase III trial. Eur J Cancer. 2019 Jan;106: 181-92. https://doi.org/10.1016/j.ejca.2018.10.015
Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, Link T, Untch M, Jackisch C, Blohmer JU, Fasching PA, Solbach C, Schmutzler RK, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S; GBG and AGO-B. Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer. 2022 Jan;160: 100-11. https://doi.org/10.1016/j.ejca.2021.10.011
Petrelli F, Tomasello G, Parati MC, Ghidini A, Ghidini M, Borgonovo K, Cabiddu M, Ghilardi M, Reduzzi R, Gambini D, Zaniboni A, Faustinelli G, Garrone O. Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials. Medicine (Kaunas). 2024 Feb 19;60(2): 341.
Lin YY, Gao HF, Yang meta-analysis. Breast. 2022 Dec;66: 126-35. https://doi.org/10.3390/medicina60020341
Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A, Palmiotti G. KEYNOTE-522, IMpassion031 and GeparNEW: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol. 2022 Jun;18(18): 2301-9. https://doi.org/10.2217/fon-2021-1647
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9): 810-21. https://doi.org/10.1056/NEJMoa1910549
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6): 556-67. https://doi.org/10.1056/NEJMoa2112651
